Source - RNS
RNS Number : 8219K
Avacta Group PLC
26 September 2016
 

26 September 2016

 

Avacta Group plc

("Avacta" or "the Group" or "the Company")

 

Notice of Results

 

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, will announce its financial results for the year ended 31 July 2016 on Monday, 17 October 2016.

 

ENDS

 

 

Notes to Editors

 

For further information from Avacta Group plc, please contact:

 

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tony Gardiner, Chief Financial Officer

 

Tel:  +44 (0) 844 414 0452

www.avacta.com

finnCap Ltd

Geoff Nash / Giles Rolls - Nominated Adviser

Tim Redfern / Alice Lane - Corporate Broking

 

Tel:  +44 (0) 207 220 0500

www.finncap.com

 

 

WG Partners

David Wilson

Nigel Barnes

Claes Spang

 

Tel:  +44 (0) 203 705 9318

Tel:  +44 (0) 203 705 9217

www.wgpartners.co.uk

 

FTI Consulting (Financial Media and IR)

Simon Conway / Natalie Garland-Collins

Tel:  +44 (0) 203 727 1000

[email protected]

 

 

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

 

Antibodies dominate markets worth in excess of $75bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of targets to enable diagnostics, research assays and therapeutics.

 

Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORSEUFSMFMSEFU

Related Charts

Avacta Group (AVCT)

0.00p (0.00%)
delayed 18:15PM